A framework is provided for understanding the neural substrates of somatic symptoms in MDD, developing somatic phenotype-based biomarkers and targeted neuromodulation therapies, and integrating systems-level neuroimaging into precision psychiatry to advance biologically informed diagnosis/treatment.
Abstract
With growing recognition that somatic symptoms constitute a clinically significant yet underexplored dimension of major depressive disorder (MDD), symptoms including sleep disturbances, gastrointestinal discomfort, pain, appetite changes, and fatigue have attracted increasing research attention. These symptoms are not only highly prevalent but are also closely associated with poor prognosis, treatment resistance, and elevated suicide risk. In this context, neuroimaging studies of the somatic manifestations of MDD have provided critical insights to advance precision diagnosis and individualized intervention. This review comprehensively integrates functional and structural neuroimaging findings on discrete somatic symptoms and somatic symptom clusters in MDD. It identifies the specific neural circuit abnormalities associated with individual symptom domains while elucidating shared pathophysiological mechanisms across symptom types, including disrupted interoceptive processing, pathological default mode network activity, and impaired sensory gating. On this basis, the review discusses the therapeutic and predictive implications of these findings and proposes future research directions oriented toward network-based brain-symptom mapping, transdiagnostic and longitudinal designs, and multimodal multilevel integration. By synthesizing existing evidence, this review provides a framework for understanding the neural substrates of somatic symptoms in MDD, developing somatic phenotype-based biomarkers and targeted neuromodulation therapies, and integrating systems-level neuroimaging into precision psychiatry to advance biologically informed diagnosis/treatment.
The neurobiological basis of cognitive impairment in MDD is explored, key biomarkers associated with these deficits are identified, and their implications for diagnosis, prognosis, and therapeutic intervention are discussed.
Akansha Thakur, Parag Jain, M. Sharma et al.· Current Behavioral Neuroscie...· 0 citations
Results indicate that multi-omics integration, in addition to explaining the molecular architecture of MDD, also characterizes patient subgroups with pathophysiological mechanisms, dimensions of symptoms, and disease treatment, which demonstrates that there is a shift in psychiatry toward a more mechanistic approach.
Elham Amjad, B. Sokouti· OBM Neurobiology· 0 citations
This review synthesizes current evidence on the unique pathophysiology, clinical management, and emerging frontiers of geriatric mental health, emphasizing the interplay of neurobiological aging, multimorbidity, and psychosocial stressors to advance precision psychiatry for LMDs.
Jin Wang, An-Qi Li· Frontiers in Psychiatry· 0 citations
This approach advances efforts toward precision neuropsychopharmacology by identifying reproducible brain–behavior relationships that may inform treatment selection and mechanistic targeting and provides a scalable framework for biologically informed subtyping in MDD.
K. Dunlop· International Journal of Neu...· 0 citations
This study delineated two MDD subtypes with distinct neuropathological profiles: one characterized by structural abnormalities across multiple brain regions and the other by widespread functional disruptions.
Z. Chen, Q. Bo, C. Wang· International Journal of Neu...· 0 citations
PURPOSE OF REVIEW
This review summarizes recent evidence on the physical health burden associated with personality disorders (PDs), focusing on physical comorbidity and multimorbidity, physical symptoms, and premature mortality.
RECENT FINDINGS
Accumulating evidence indicates that individuals with PDs experience mark...
Ivona Šimunović Filipčić, I. Filipčić, Ivana Jurčić Čulina et al.· Current Opinion in Psychiatr...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.